Personalized prostate MRI protocol: Selective contrast enhancement for PI-RADS 3 lesions to optimize diagnostic accuracy and resource utilization

Background The operational burden on radiology departments worldwide has intensified the need for efficient imaging protocols. Purpose To compare the efficacies of biparametric magnetic resonance imaging (bpMRI) and multiparametric MRI (mpMRI) in detecting prostate cancer in terms of diagnostic accuracy, acquisition time, and cost, and to propose a personalized imaging protocol with selective contrast medium administration for prostate imaging reporting and data system (PI-RADS) 3 lesions. Material and Methods This study's sample consisted of 1004 patients who underwent prostate mpMRI between 2017 and 2023. Two independent radiologists evaluated cases that underwent bpMRI (T2/DWI) and then mpMRI, per PI-RADS v2.1 guidelines. Inter-protocol agreement was assessed using Cohen's Kappa coefficients. Cost and budget impact analysis was used to compare the methods in terms of cost, acquisition time, and number needed to scan (NNS) to detect one additional malignancy. Results Inter-protocol agreement between bpMRI and mpMRI was excellent (κ = 0.951, 95% confidence interval (CI) 0.933–0.969; P < 0.001). The malignancy rate among lesions upgraded from PI-RADS 3 on bpMRI to PI-RADS 4 on mpMRI was significantly higher compared to lesions remaining PI-RADS 3 (66.7% (18/27), 95% CI 47.8–81.4 vs. 19.4% [13/67], 95% CI 11.7–30.4; P < 0.001). Conclusion bpMRI demonstrated high diagnostic performance for detecting prostate cancer, particularly for PI-RADS 1, 2, and 5 lesions. A personalized triage strategy—reserving dynamic contrast enhancement selectively for lesions initially categorized as PI-RADS 3 on bpMRI—offers a pragmatic balance. Rather than an absolute optimal strategy, this approach achieves the higher sensitivity of mpMRI while significantly optimizing acquisition time and costs, accompanied by a recognized and acceptable trade-off in specificity.

Authors

Institutions

Publication Details

Journal
Acta Radiologica
Published
2026-11-19
DOI
https://doi.org/10.1177/02841851261508752
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Personalized prostate MRI protocol: Selective contrast enhancement for PI-RADS 3 lesions to optimize diagnostic accuracy and resource utilization

Ahmet Faruk Gürbüz, Ayşe Keven, İsmail Özgül, Süleyman Metin Çubuk
Acta Radiologica
Prostate Cancer Diagnosis and Treatment
article

Personalized prostate MRI protocol: Selective contrast enhancement for PI-RADS 3 lesions to optimize diagnostic accuracy and resource utilization

Ahmet Faruk Gürbüz, Ayşe Keven, İsmail Özgül, Süleyman Metin Çubuk
article en

Abstract

Background The operational burden on radiology departments worldwide has intensified the need for efficient imaging protocols. Purpose To compare the efficacies of biparametric magnetic resonance imaging (bpMRI) and multiparametric MRI (mpMRI) in detecting prostate cancer in terms of diagnostic accuracy, acquisition time, and cost, and to propose a personalized imaging protocol with selective contrast medium administration for prostate imaging reporting and data system (PI-RADS) 3 lesions. Material and Methods This study's sample consisted of 1004 patients who underwent prostate mpMRI between 2017 and 2023. Two independent radiologists evaluated cases that underwent bpMRI (T2/DWI) and then mpMRI, per PI-RADS v2.1 guidelines. Inter-protocol agreement was assessed using Cohen's Kappa coefficients. Cost and budget impact analysis was used to compare the methods in terms of cost, acquisition time, and number needed to scan (NNS) to detect one additional malignancy. Results Inter-protocol agreement between bpMRI and mpMRI was excellent (κ = 0.951, 95% confidence interval (CI) 0.933–0.969; P < 0.001). The malignancy rate among lesions upgraded from PI-RADS 3 on bpMRI to PI-RADS 4 on mpMRI was significantly higher compared to lesions remaining PI-RADS 3 (66.7% (18/27), 95% CI 47.8–81.4 vs. 19.4% [13/67], 95% CI 11.7–30.4; P < 0.001). Conclusion bpMRI demonstrated high diagnostic performance for detecting prostate cancer, particularly for PI-RADS 1, 2, and 5 lesions. A personalized triage strategy—reserving dynamic contrast enhancement selectively for lesions initially categorized as PI-RADS 3 on bpMRI—offers a pragmatic balance. Rather than an absolute optimal strategy, this approach achieves the higher sensitivity of mpMRI while significantly optimizing acquisition time and costs, accompanied by a recognized and acceptable trade-off in specificity.

Acta Radiologica
Akdeniz University (TR)
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon